Infliximab Production Cost Reports

The report provides a detailed analysis essential for establishing an Infliximab production plant. It encompasses all critical aspects necessary for Infliximab production, including the cost of Infliximab production, Infliximab plant cost, Infliximab production costs, and the overall Infliximab production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an Infliximab production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Infliximab is a biologic medication used primarily in the treatment of autoimmune and inflammatory diseases. It is widely used for the treatment of various inflammatory and autoimmune conditions, including rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. It works by targeting and blocking tumour necrosis factor-alpha (TNF-α), which is a protein involved in the inflammatory process. It is administered through intravenous infusion in a clinical or hospital setting. It is also used in the management of certain skin conditions, such as psoriasis, and in some cases, to treat chronic inflammatory diseases of the eyes. Moreover, it is often used in research to explore its potential applications in other inflammatory diseases.

The market for Infliximab is primarily driven by its application as a drug for the treatment of various chronic inflammatory conditions, which significantly boosts its demand in the medical sector. Its application as a medication in the treatment of conditions like rheumatoid arthritis, Crohn's disease, ulcerative colitis, and ankylosing spondylitis also contributes to its demand in the pharmaceutical industry.

Its usage in the treatment of inflammatory conditions, including psoriatic arthritis and certain skin disorders, also contributes to its demand in the healthcare and pharmaceutical industries. Its demand as an important drug in modern medicine to treat autoimmune or immune-mediated disorders largely fuels its market expansion. In addition, industrial procurement processes are influenced by factors such as the availability of high-quality biologic raw materials, strict regulatory and biosafety requirements, and compliance with production standards. The rising prevalence of autoimmune disorders, expanding biologics pipelines, and increased healthcare spending further contribute to its market demand. Moreover, advancements in bioproduction technologies, dependable supply chains, sustainability practices, and efficient cold-chain logistics also play an important role in shaping global industrial Infliximab procurement.

Raw Material for Infliximab Production

According to the Infliximab production plant project report, the major raw materials for Infliximab production includes Murine hybridoma SP2/0 cells.

Production Process of Infliximab

The extensive Infliximab production cost report consists of the following industrial production process:

1. Production via Chemical Synthesis: The production process of Infliximab begins with the cultivation of a recombinant cell line using continuous perfusion to produce the protein. Then, these cells are harvested, and the product undergoes a series of purification steps, including measures to inactivate and remove viruses. The final product is then purified to obtain Infliximab.

Infliximab is a chimeric monoclonal antibody that appears as a white to off-white lyophilised powder when formulated for intravenous administration. The compound is a large glycoprotein consisting of two light chains and two heavy chains with an approximate molecular weight of 149,000 g/mol or 149 kDa. Each light chain consists of 214 amino acids (23,435 Da), and each heavy chain has 450 amino acids (50,826 Da), including glycosylation at asparagine residue 300 in the Fc region. The median terminal elimination half-life is 7.7 to 9.5 days following intravenous infusion. Serious adverse effects include increased risk of serious infections such as tuberculosis, invasive fungal infections, and bacterial sepsis, as well as infusion-related reactions, hepatotoxicity, heart failure, and hypersensitivity reactions. It is recommended that patients be screened for latent tuberculosis infection before initiating therapy, and treatment should be administered under the supervision of experienced healthcare professionals. The patient should also be monitored for infections and infusion reactions throughout the course of therapy.